Does the use of lapatinib increase the risk of fatigue and hepatic toxicities in patients with solid tumors? A critical literature review and meta-analysis

Expert Opinion on Drug Safety

Volumn 13, Issue 8, 2014, Pages 999-1008

  Abdel Rahman, Omar ^a   Fouad, Mona ^a  

^a AIN SHAMS UNIVERSITY   (Egypt)

Author keywords

Fatigue; Hepatotoxicity; Lapatinib; Meta analysis

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; LAPATINIB; ANTINEOPLASTIC AGENT; QUINAZOLINE DERIVATIVE;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; DRUG EFFECT; DRUG USE; FATIGUE; HUMAN; LIVER TOXICITY; META ANALYSIS; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); REVIEW; RISK ASSESSMENT; SOLID TUMOR; SYSTEMATIC REVIEW; CHEMICALLY INDUCED; DRUG-INDUCED LIVER INJURY; NEOPLASMS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK;

ANTINEOPLASTIC AGENTS; DRUG-INDUCED LIVER INJURY; FATIGUE; HUMANS; NEOPLASMS; QUINAZOLINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK;

EID: 84904462742     PISSN: 14740338     EISSN: 1744764X     Source Type: Journal    
DOI: 10.1517/14740338.2014.921679     Document Type: Review

References (36)

1. Paul B, Trovato JA, Thompson J. Lapatinib: A dual tyrosine kinase inhibitor for metastatic breast cancer. Am J Health Syst Pharm 2008;65(18):1703-10
2. Untch M, Lück HJ. Lapatinib-Member of a new generation of ErbB-Targeting drugs. Breast Care (Basel) 2010;5(s1):8-12
3. Abdel-Rahman O. Systemic therapy for hepatocellular carcinoma (HCC): From bench to bedside. J Egypt Natl Canc Inst 2013;25(4):165-71
4. Abdel-Rahman O, Abdelwahab M, Shaker M, et al. Sorafenib versus capecitabine in the management of advanced hepatocellular carcinoma. Med Oncol 2013;30(3):655
5. Tykerb (lapatinib) FDA prescribing information. Available from: Http://www. accessdata.fda.gov/drugsatfda-docs/label/ 2010/022059s007lbl.pdf
6. Abdel-Rahman O, Elsayed Z. Combination trans arterial chemoembolization (TACE) plus sorafenib for the management of unresectable hepatocellular carcinoma: A systematic review of the literature. Dig Dis Sci 2013;58(12):3389-96
7. Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group. Preferred reporting items for systematic reviews and meta-Analyses: The PRISMA statement. J Clin Epidemiol 2009;62(10):1006-12
8. National cancer institute, common toxicity criteria. Available from: Http:// ctep.cancer.gov/protocoldevelopment/ electronic-applications/docs/ ctcaev3.pdf
9. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta analyses. BMJ 2003;327(7414):557-60
10. DerSimonian R, Laird N. Meta-Analysis in clinical trials. Control Clin Trials 1986;7(3):177-88
11. Hicks DG, Whitney-Miller CL. The evolving role of HER2 evaluation for diagnosis and clinical decision making for breast and gastric adenocarcinoma. Biotech Histochem 2013;88(3-4):121-31
12. Cui H, Cheng Y, Piao SZ, et al. Correlation between HER-2/neu(erbB-2) expression level and therapeutic effect of combination treatment with HERCEPTIN and Chemotherapeutic agents in gastric cancer cell lines. Cancer Cell Int 2014;14(1):10
13. Konecny GE, Pegram MD, Venkatesan N, et al. Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-Treated breast cancer cells. Cancer Res 2006;66(3):1630-9
14. Baselga J, Bradbury I, Eidtmann H. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): A randomised, open-label, multicentre, phase 3 trial. Lancet 2012;379(9816):633-40
15. Untch M, Loibl S, Bischoff J. Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-Taxane-based chemotherapy (GeparQuinto, GBG 44): A randomised phase 3 trial. Lancet Oncol 2012;13(2):135-44
16. Johnson BE, Kabbinavar F, Fehrenbacher L, et al. ATLAS: Randomized, double-blind, placebocontrolled, phase IIIB trial comparing bevacizumab therapy with or without erlotinib, after completion of chemotherapy, with bevacizumab for first-line treatment of advanced non-small-cell lung cancer. J Clin Oncol 2013;31(31):3926-34
17. Abdel-Rahman O, Abdelwahab M, Shaker M, et al. Sorafenib for Egyptian patients with advanced hepatocellular carcinoma; single center experience. J Egypt Natl Cancer Inst 2014;26(1):9-13
18. Abdel-Rahman O, Fouad M. Sorafenib-based combination as a first line treatment for advanced hepatocellular carcinoma: A systematic review of the literature. Crit Rev Oncol Hematol 2014;91:1-8. doi: 10.1016/j. critrevonc.2013.12.013
19. Ensslin CJ, Rosen AC, Wu S, Lacouture ME. Pruritus in patients treated with targeted cancer therapies: Systematic review and meta-Analysis. J Am Acad Dermatol 2013;69(5):708-20
20. Martin M, Bonneterre J, Geyer CE Jr, et al. A phase two randomised trial of neratinib monotherapy versus lapatinib plus capecitabine combination therapy in patients with HER2+ advanced breast cancer. Eur J Cancer 2013;49(18):3763-72
21. Decensi A, Puntoni M, Pruneri G. Lapatinib activity in premalignant lesions and HER-2-positive cancer of the breast in a randomized, placebo-controlled presurgical trial. Cancer Prev Res (Phila) 2011;4(8):1181-9
22. Drugs. Com. Available from: Http:// www.drugs.com/labeling-changes/ August-2011/tykerb-lapatinib-1999.html [Last accessed 25 February 2014]
23. Shah RR, Morganroth J, Shah DR. Hepatotoxicity of tyrosine kinase inhibitors: Clinical and regulatory perspectives. Drug Saf 2013;36(7):491-503
24. Abdel-Rahman O, Fouad M. Risk of mucocutaneous toxicities in patients with solid tumors treated with sorafenib: An updated systematic review and meta-Analysis. Expert Rev Anticancer Ther 2014;14(6):751-60
25. Spraggs CF, Budde LR, Briley LP, et al. HLA-DQA1*02:01 is a major risk factor for lapatinib-induced hepatotoxicity in women with advanced breast cancer. J Clin Oncol 2011;29(6):667-73
26. Robidoux A, Tang G, Rastogi P. Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41): An open-label, randomised phase 3 trial. Lancet Oncol 2013;14(12):1183-92
27. Johnston SR, Gómez H, Stemmer SM. A randomized and open-label trial evaluating the addition of pazopanib to lapatinib as first-line therapy in patients with HER2-positive advanced breast cancer. Breast Cancer Res Treat 2013;137(3):755-66
28. Cristofanilli M, Johnston SR, Manikhas A, et al. A randomized phase II study of lapatinib + pazopanib versus lapatinib in patients with HER2+ inflammatory breast cancer. Breast Cancer Res Treat 2013;137(2):471-82
29. Goss PE, Smith IE, O'shaughnessy J. Adjuvant lapatinib for women with early-stage HER2-positive breast cancer: A randomised, controlled, phase 3 trial. Lancet Oncol 2013;14(1):88-96
30. Verma S, Miles D, Gianni L, et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med 2012;367(19):1783-91
31. Guarneri V, Frassoldati A, Bottini A. Preoperative chemotherapy plus trastuzumab, lapatinib, or both in human epidermal growth factor receptor 2-positive operable breast cancer: Results of the randomized phase II CHER-LOB study. J Clin Oncol 2012;30(16):1989-95
32. Monk BJ, Mas lopez L, Zarba JJ. Phase II, open-label study of pazopanib or lapatinib monotherapy compared with pazopanib plus lapatinib combination therapy in patients with advanced and recurrent cervical cancer. J Clin Oncol 2010;28(22):3562-9
33. Di Leo A, Gomez HL, Aziz Z, et al. Phase III, double blind, randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as first-line treatment for metastatic breast cancer. J Clin Oncol 2008;26(34):5544-52
34. Ravaud A, Hawkins R, Gardner JP. Lapatinib versus hormone therapy in patients with advanced renal cell carcinoma: A randomized phase III clinical trial. J Clin Oncol 2008;26(14):2285-91
35. Geyer CE, Forster J, Lindquist D, et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 2006;355(26):2733-43
36. Guan Z, Xu B, DeSilvio ML, et al. Randomized trial of lapatinib versus placebo added to paclitaxel in the treatment of human epidermal growth factor receptor 2-overexpressing metastatic breast cancer. J Clin Oncol 2013;31(16):1947-53